CHS 828 in Treating Patients With Solid Tumors

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of CHS 828 in treating patients who have solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed solid tumor not amenable to standard therapy

• No symptomatic brain or leptomeningeal involvement

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• WHO 0-2

Life expectancy:

• At least 3 months

Hematopoietic:

• WBC at least 4,000/mm^3

• Platelet count at least 100,000/mm^3

Hepatic:

• Bilirubin less than 1.5 mg/dL

• Other liver function tests no greater than 2 times upper limit of normal (unless related to liver metastases)

Renal:

• Creatinine no greater than 1.4 mg/dL

Other:

• Not pregnant or nursing

• Fertile patients must use effective contraception

• No active bacterial infection

• No other nonmalignant disease

• No alcoholism, drug addiction, or psychiatric disorders

• Able to take oral medication

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• At least 4 weeks since prior immunotherapy

Chemotherapy:

• At least 4 weeks since prior chemotherapy (6 weeks since nitrosoureas)

• No other concurrent chemotherapy

Endocrine therapy:

• Not specified

Radiotherapy:

• At least 4 weeks since prior radiotherapy (6 weeks since extensive radiotherapy)

• No concurrent radiotherapy (except palliative radiotherapy)

Surgery:

• Not specified

Other:

• No other concurrent investigational drugs

• No other concurrent antitumor drugs